Short answer: SR9011 is a synthetic REV-ERB agonist, a sister compound of SR9009 (Stenabolic), developed at Scripps as a research tool for the body clock. It has never been tested in people. In mice, injected SR9011 increased energy use, reduced fat mass and changed sleep and daily activity patterns (Solt 2012). Any SR9011 dosage or “before and after” result for humans is anecdotal. It is banned in sport and, in Australia, prescription-only with possession controls.
| Question | Answer | Evidence |
|---|---|---|
| Is it a SARM? | No, it targets REV-ERB, not the androgen receptor | Animal/cell |
| Human studies | None | None |
| Fat loss | Less fat mass and 5% higher oxygen use in mice given it twice daily | Animal |
| Half-life | Not established in humans | None |
| Testosterone | Not measured | None |
| Sport | Prohibited at all times (WADA S4.4.1) | Regulator |
What Is SR9011
SR9011 is a synthetic agonist of REV-ERB-alpha and REV-ERB-beta, nuclear receptors that help run the body clock and switch metabolic genes in the liver, muscle and fat on and off. It was published together with SR9009 in 2012 as one of the first REV-ERB drugs that worked in living animals (Solt 2012).
The old version of this page said SR9011 is “non-hormonal” and therefore never needs PCT. Its effect on testosterone has simply never been measured, in animals or people, so that is not established. It does act on the body’s clock, sleep and metabolism, which are not neutral.
Is SR9011 legal?
SR9011 is not an approved medicine anywhere we could find, and it is sold as a “research chemical”. Its legal status depends on the country; the old claim that it is legal everywhere except Australia was not something we could confirm. Germany’s Anti-Doping Act, for example, lists SR9009 (AntiDopG annex). For SARMs by country, see are SARMs legal and SARMs in Europe.
Australia
In Australia, “Stenabolic (SR9009) and other synthetic REV-ERB agonists”, cross-referenced to SR9011, are Schedule 4 (prescription only) and in Appendix D, clause 5, so possession without authority is illegal (Poisons Standard, June 2026). Earlier versions of this page said Schedule 9; that is not the current listing. Read more in SARMs in Australia.
competitive sports
The WADA 2026 Prohibited List names SR9009 and SR9011 as Rev-erb-alpha agonists under S4.4.1, metabolic modulators, prohibited at all times (WADA 2026). Anti-doping labs have mapped SR9011’s breakdown products so they can test for it (Geldof 2016).
SR9011 benefits
All of the benefits below come from animal or cell studies; none has been shown in people.
- Fat and energy use: mice given SR9011 twice a day for 10 days used about 5% more oxygen, a sign of higher energy expenditure, while moving 15% less; longer treatment reduced fat mass without changing food intake (Solt 2012).
- Endurance: activating REV-ERB-alpha increased exercise capacity in mice (Woldt 2013); this was not tested with SR9011 in people.
- Anxiety: REV-ERB agonists reduced anxiety-like behavior in mice (Banerjee 2014).
- Cancer cells: SR9009 and SR9011 killed cancer cells but not normal cells in lab tests, and slowed brain tumors in mice (Sulli 2018).
- Muscle mass: not shown in any study we found.
SR9011 side effects
Side effects in people are not established, because no human has taken SR9011 in a study. What the research flags:
- Sleep: in mice, a single dose shifted daily activity, and REV-ERB agonists increased wakefulness and reduced REM and deep sleep (Solt 2012, Banerjee 2014). Users report insomnia (anecdotal).
- Off-target effects: the sister compound SR9009 changed cell survival and metabolism even in cells lacking REV-ERB (Dierickx 2019), so these drugs do more than their target suggests.
- Liver: no SR9011 data, but SR9009 has been linked to liver injury, including acute liver failure needing a transplant in a 17-year-old (Shams Bin Shaheen 2026).
Where to buy SR9011
SR9011 is sold online as a research chemical, so what is in a bottle is not checked by any regulator. In tests of products sold as SARMs, only 52% contained a SARM and 39% contained another unapproved drug (Van Wagoner 2017). If you are in a country where buying it is allowed, look for a seller that publishes an independent lab report for each batch; our current pick and the reasons are in the SwissChems review.
SR9011 half-life
The human half-life of SR9011 is not established. The old version of this page gave 4 hours (and quoted it for SR9009), with no source. In the mouse studies it was injected twice a day (Solt 2012). Users commonly split doses two or three times a day on the assumption of a short half-life; that has never been tested.
SR9011 Dosage
There is no researched SR9011 dosage for people. Users commonly report 15–30 mg a day split into two or three doses (anecdotal). In mice, the effective doses were around 50–100 mg per kg of body weight by injection (for example, half the maximal effect on running-wheel activity at 56 mg/kg) (Solt 2012); animal doses like these cannot be converted into a safe human dose. More detail in our SR9011 dosage, side effects and benefits guide.
SR9011 before and after: what to expect
We have no SR9011 before and after photos, and no study has measured body changes in people. What exists:
| Source | What changed |
|---|---|
| Mice, 10 days of SR9011 twice daily (Solt 2012) | Oxygen use +5%, movement −15% |
| Mice, longer treatment (Solt 2012) | Weight loss from lower fat mass; food intake unchanged |
| User reports | More endurance and some fat loss over 4–8 weeks, usually stacked with other compounds (anecdotal) |
Most “before and after” pictures attributed to SR9011 online are stacks with SARMs and come with a diet. Compare with reader results on the cardarine and SARMs before and after pages, several of which include SR9009.
SR9011 vs SR9009
SR9011 and SR9009 were described in the same 2012 paper and act on the same targets (Solt 2012). In cell tests their potencies were similar (SR9009: IC50 670 nM on REV-ERB-alpha; SR9011: 790 nM). Both are named together on the WADA list and in the Australian Poisons Standard.
The common claim that SR9011 has much better bioavailability than SR9009 is not established: no human study has measured either one, and we found no published comparison. SR9009 is more widely sold and discussed. Read more in our Stenabolic review and SR9009 dosage.
Conclusion
SR9011 is an experimental body-clock drug, not a SARM, with interesting results in mice (more energy use, less fat, altered sleep) and no human data at all. Claims about its bioavailability, half-life, “no PCT” status and dose are not established, and its sister compound SR9009 has now been linked to serious liver injury. It is banned in sport and controlled in Australia. Compare it with compounds that have human evidence in the SARMs database.
Frequently asked questions
Is SR9011 a SARM?
NoEvidence: Lab
SR9011 activates REV-ERB, a body-clock protein, not the androgen receptor. It is often sold alongside SARMs.
What does SR9011 do?
Unknown in peopleEvidence: Animal
In mice it increased oxygen use (a sign of higher energy expenditure), reduced fat mass and altered sleep and daily activity. None of this has been tested in people.
What is the SR9011 dosage?
No researched human doseEvidence: Limited
No dose has been studied in people; doses quoted online come from user reports. Mouse doses of around 50–100 mg/kg by injection cannot be converted to humans.
What is the half-life of SR9011?
Not established in humansEvidence: Limited
No human half-life has been measured. The 4-hour figure often quoted has no published source.
Does SR9011 require PCT?
UnknownEvidence: Limited
Its effect on testosterone has never been measured. It does not act on the androgen receptor, but "no PCT needed" has not been shown either.
What are SR9011 before and after results?
No human dataEvidence: Animal
There are no human studies or verified photos; in mice, longer treatment led to weight loss from lower fat mass. User reports of more endurance and fat loss over 4–8 weeks are anecdotal and usually involve stacks.
Is SR9011 legal?
Not an approved medicineEvidence: Law
In Australia, SR9011 is covered as a synthetic REV-ERB agonist in Schedule 4 with possession controls, and WADA bans it in sport at all times. Other countries vary.
Sources
- Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists
- Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy
- Pharmacological targeting of the mammalian clock regulates sleep architecture and emotional behaviour
- Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence
- SR9009 has REV-ERB-independent effects on cell proliferation and metabolism
- Acute Liver Failure in an Adolescent Following Use of the Synthetic REV-ERB Agonist SR9009
- In Vitro Metabolic Studies of REV-ERB Agonists SR9009 and SR9011
- Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet
- Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026 (F2026L00633)
- Anlage zum Anti-Doping-Gesetz (AntiDopG) – gesetze-im-internet.de
- WADA: The Prohibited List (2026 List, in force from 1 January 2026)
- PubChem: SR9011 (CID 57394021), names and synonyms